EUCTR2012-005087-10-AT进行中（未招募）不适用
A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in COPD patients with moderate to severe airflow limitation
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 554
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients who have signed an Informed Consent Form prior to initiation of any study-related procedure
- •- Male and female adults aged =40 years
- •- Patients with stable COPD according to the current GOLD strategy (GOLD 2011)
- •- Patients with airflow limitation indicated by a post-bronchodilator FEV1 = 30% and < 80% of the predicted normal, and a post-bronchodilator
- •FEV1/FVC < 0.7 at run-in (Visit 101)
- •- Current or ex-smokers who have a smoking history of at least 10 pack years (e.g., 10 pack years = 1 pack/day x 10 years, or ½ pack/day x 20 years). An ex-smoker may be defined as a subject who has not smoked for = 6 months at screening
- •- Patients with an mMRC grade 2 or greater at Visit 101
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 288
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 266
排除标准
- •1. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG (human Chorionic Gonadotropin) laboratory test.
- •2. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment. Effective contraception methods include:
- •Total abstinence when this is in line with the preferred and usual lifestyle of the
- •subject (periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation
- •methods) and withdrawal are not acceptable methods of contraception).
- •Female sterilization defined as surgical hysterectomy, bilateral oophorectomy, or
- •tubal ligation at least six weeks before taking the study treatment (Single
- •oophorectomy does not meet the definition of female sterilization).
- •Male sterilization (at least 6 months prior to screening). For female subjects on the
- •study, the vasectomized male partner should be the sole partner for that subject.
- •Barrier methods of contraception: Condom or Occlusive cap (diaphragm or
- •cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.
- •Use of oral, injected or implanted hormonal methods of contraception or other forms
- •of hormonal contraception that have comparable efficacy (failure rate <1%), for
- •example hormone vaginal ring or transdermal hormone contraception. In case of use
- •of oral contraception women should have been stable on the same pill for a minimum
- •of 3 months before taking study treatment.
- •Placement of an intrauterine device (IUD) or intrauterine system (IUS).
- •Women are considered post-menopausal and not of child bearing potential if they have
- •had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile
- •(e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral
- •oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In
- •the case of oophorectomy alone, only when the reproductive status of the woman has been
- •confirmed by follow up hormone level assessment is she considered not of child bearing
- •3. Patients with Type I or uncontrolled Type II diabetes.
- •4. Patients with a history of long QT syndrome or whose QTc measured at Visit 101
- •(Fridericia method) is prolonged (>450 ms for males and females) and confirmed by a
- •central laboratory. These patients should not be re-screened.
- •5. Patients who have a clinically significant ECG abnormality at Visit 101 or Visit 102.
- •These patients should not be re-screened.
- •6. Patients who have a clinically significant laboratory abnormality at Visit 101.
- •7. Patients with a body mass index (BMI) of more than 40 kg/m2.
- •8. Patients who have clinically significant renal, cardiovascular (such as but not limited to
- •unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, myocardial
- •infarction), arrhythmia (see below for patients with atrial fibrillation), neurological,
- •endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological
- •abnormalities which could interfere with the assessment of the efficacy and safety of the
- •study treatment.
- •For more exclusion criteria, please refer to the protocol.
研究者
相似试验
进行中（未招募）
1 期
Study of efficacy and safety of QVA149 compared to standard of care, acombination of fluticasone/salmeterol, in patients with moderate to severeCOPDEUCTR2012-005102-22-CZovartis Pharma AG555
进行中（未招募）
不适用
A multi-centre randomized double blind 12-week study to assess the efficacy, safety and tolerability of QVA149 in patients with COPD who have moderate to severe airflow limitatioChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2012-003346-32-PLovartis Pharma Services AG1,000
已完成
3 期
A 12 week study to assess theefficacy and safety of switching from salmeterol/fluticasone to QVA149 in symptomatic COPDpatients.CTRI/2015/08/006128ovartis Healthcare Pvt Ltd88
进行中（未招募）
不适用
A 12-week treatment, multi-center, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 µg o.d.) in patients with chronic obstructive pulmonary disease.COPD: chronic obstructive pulmonary diseaseMedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-000301-11-DEovartis Pharma Services AG450
进行中（未招募）
不适用
A multi-centre randomized double blind 12-week study to assess the efficacy, safety and tolerability of QVA149 in patients with COPD who have moderate to severe airflow limitatioChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2012-003347-30-HUovartis Pharma Services AG1,000